Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $20.00 Price Target at Robert W. Baird

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price objective lowered by Robert W. Baird from $26.00 to $20.00 in a research report sent to investors on Tuesday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.

A number of other brokerages have also weighed in on ENTA. JMP Securities restated a “market outperform” rating and issued a $21.00 price objective (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday. Evercore ISI raised shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th. Finally, JPMorgan Chase & Co. decreased their price objective on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a report on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.50.

Enanta Pharmaceuticals Trading Up 3.2 %

Shares of Enanta Pharmaceuticals stock opened at $8.83 on Tuesday. The firm has a market capitalization of $187.11 million, a PE ratio of -1.61 and a beta of 0.56. Enanta Pharmaceuticals has a 12 month low of $8.00 and a 12 month high of $17.80. The business’s 50-day moving average price is $10.87 and its 200-day moving average price is $12.28.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ENTA. Allspring Global Investments Holdings LLC purchased a new stake in shares of Enanta Pharmaceuticals during the second quarter worth about $35,000. US Bancorp DE raised its position in Enanta Pharmaceuticals by 4,933.7% during the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 4,243 shares during the last quarter. State Board of Administration of Florida Retirement System purchased a new stake in Enanta Pharmaceuticals in the 1st quarter worth approximately $118,000. Virtu Financial LLC bought a new stake in shares of Enanta Pharmaceuticals in the 1st quarter worth approximately $191,000. Finally, Quest Partners LLC grew its position in shares of Enanta Pharmaceuticals by 511.2% in the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $150,000 after buying an additional 9,692 shares during the last quarter. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.